Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching amyotrophic lateral sclerosis (ALS) may encounter iPSC-derived motor neuron precursor therapy as an emerging cell-based treatment approach. In China, this therapy is currently available through the Hainan Boao Lecheng domestic pilot-use pathway. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is ALS Stem Cell Therapy China Using iPSC-Derived Motor Neuron Precursors?
ALS stem cell therapy China may include investigational approaches using motor neuron precursor cells derived from human induced pluripotent stem cells (iPSCs). In this approach, the motor neuron precursor cells are administered by lumbar puncture injection, with the goal of supporting or replacing damaged motor neurons affected by amyotrophic lateral sclerosis (ALS).
This approach differs from gene-modified cell therapies because the key feature is the use of motor neuron precursor cells derived from human iPSCs rather than cells specifically described as being genetically modified for the treatment. ALS stem cell therapy China remains an investigational treatment approach, and its safety and effectiveness continue to be evaluated through clinical research.
The therapy received FDA orphan drug designation in 2023 and was approved for national-level clinical trial registration in China in 2024 for a Phase I/II study. These regulatory and clinical-development milestones indicate that the therapy is being investigated, but they do not establish that it is proven effective or appropriate for every patient with ALS.
Is iPSC-Derived Motor Neuron Precursor Therapy for ALS Available in China?
Yes, but access is through a specific Hainan pilot pathway, rather than general nationwide availability. The therapy was licensed for domestic pilot use in Hainan on May 26, 2026.
For international patients, this distinction is important. A Hainan pilot-use authorization does not mean the treatment has received nationwide approval for routine use throughout China. Availability also remains subject to medical assessment and the applicable access requirements at the treating hospital.
Where Is iPSC-Derived Motor Neuron Precursor Therapy for ALS Offered?
The treatment is offered at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital (Hainan Boao Research Hospital) in Hainan.
Technical support is provided by Shizhe Biopharmaceuticals (Suzhou) Co., Ltd.
The treatment uses lumbar puncture to administer motor neuron precursor cells derived from human iPSCs.
Who May Be Eligible for iPSC-Derived Motor Neuron Precursor Therapy for ALS?
Eligibility criteria include:
Age 18–65.
Clinically confirmed sporadic or familial ALS diagnosis by a neurology specialist.
Early-to-mid disease stage rather than end-stage disease.
Ability to tolerate cell transplantation.
Traditional medications such as riluzole or edaravone have been insufficiently effective.
Exclusions include end-stage ALS with severe respiratory failure, tracheostomy or dysphagia; intracranial tumors; severe cardio-cerebrovascular disease; active infections; multi-organ failure; active autoimmune crisis; pregnancy or breastfeeding; and allergy to auxiliary materials.
Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does iPSC-Derived Motor Neuron Precursor Therapy for ALS Cost?
The estimated cost is ¥240,000 (approximately US$35,700) per session. The USD figure uses an approximate exchange rate of ¥6.72 per US$1.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel expenses. Confirm final pricing and the full scope of included services directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients with ALS, access to an emerging cell-based therapy through a supervised pilot pathway may provide another option to discuss with specialists, particularly when standard medications have been insufficiently effective.
The treatment remains under clinical evaluation. A reported three-patient follow-up found that the median ALSFRS-R decline slowed from 12% to 4% at 7.5 months, with no serious adverse events reported. Because this was a very small patient group, the finding should not be interpreted as establishing an expected outcome for other patients.
How iPSC-Derived Motor Neuron Precursor Therapy for ALS Fits Into the Current Evidence
The therapy's regulatory and clinical-development milestones provide context for patients considering access. FDA orphan drug designation was granted in 2023, followed by national-level clinical trial registration approval in 2024 for Phase I/II research. The 2026 Hainan domestic pilot-use license establishes an access pathway in that pilot zone, but it does not establish nationwide approval or guarantee an individual treatment outcome.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and ALS-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital (Hainan Boao Research Hospital) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is iPSC-derived motor neuron precursor therapy for ALS available in China?
Yes. It is licensed for domestic pilot use in Hainan and is offered at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital. This pilot authorization is not nationwide approval.
How much does iPSC-derived motor neuron precursor therapy for ALS cost in China?
The estimated cost is US$35,700 (¥240,000) per session. Patients should confirm final pricing and inclusions directly with the hospital.
Who may qualify for iPSC-derived motor neuron precursor therapy for ALS?
Adults aged 18–65 with a clinically confirmed sporadic or familial ALS diagnosis may be considered if they are in an early-to-mid disease stage and can tolerate cell transplantation. Final eligibility requires medical assessment.
Can international patients access this ALS therapy in China?
International patients can explore the treatment pathway through medical assessment and hospital coordination, subject to the hospital's eligibility and access requirements.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
